Effectiveness of Measuring Local Tissue Oxygen in Response to Induced Hemodynamic Changes With the Profusa's Wireless Lumee Oxygen Platform in Patients With Peripheral Artery Disease (PAD)

Status: Unknown
Location: See all (3) locations...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The purpose of this study is to monitor changes in local tissue oxygen levels in participants with Peripheral Artery Disease (PAD) using the Wireless Lumee Oxygen Platform. A transcutaneous oxygen pressure (TcPO2) device is used to show correlations in oxygen dynamics. Oxygen dynamics are induced by a pressure cuff and position maneuvers. Study participants will participate in the study for 12 months with six (6) planned visits over the course of the study. The investigational device, the Wireless Lumee Oxygen Platform, consists of the Lumee Oxygen, a sterile soft injectable oxygen-sensitive hydrogel, designed to sense and report oxygen levels in the subcutaneous tissue. After initial insertion of the hydrogel in the subcutaneous tissue using the Lumee Pen (a sterile disposable injector device), tissue oxygen levels can be monitored continuously using the Lumee Patch (a non-invasive, non-sterile, wireless electronic device to collect, analyze and report tissue oxygen levels sensed by Lumee Oxygen Hydrogel) attached to the skin through the Lumee Patch Adhesive (designed to adhere the Lumee Patch). The Lumee Patch sends collected tissue oxygen data to the Lumee App which displays the collected data and operates up to four Lumee Patches.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

⁃ A suitable candidate must meet the following criteria:

• Male or female must be ≥ 18 years of age

• Diagnosed with PAD, stable at time of enrollment, and may include prior stable lower extremity revascularization

• Has been informed of the nature of the study, agrees to its provisions, and has signed the informed consent form prior to any study related procedure

• Should plan to be available for all safety follow-up examinations at the investigational site

• Is aware that the Lumee™ Oxygen hydrogels are intended to stay in the tissue indefinitely

• Is aware that photos of injection sites and wound site will be taken, and videos may be recorded

Locations
United States
California
San Francisco General Hospital
RECRUITING
San Francisco
San Francisco Veterans Affairs Medical Center (SFVAMC)
RECRUITING
San Francisco
UCSF Medical Center
RECRUITING
San Francisco
Contact Information
Primary
Taylor Noriega, PharmD
taylor.noriega@profusa.com
415.655.9861
Backup
Monica Lozano, PhD
monica.lozano@profusa.com
415.655.9861
Time Frame
Start Date: 2020-12-18
Completion Date: 2022-05
Participants
Target number of participants: 53
Treatments
Other: Tissue Oxygen Dynamics with Lumee Oxygen and TcPO2
Monitoring local subcutaneous tissue oxygen dynamics using the Wireless Lumee Oxygen Platform in correlation to TcPO2 measurements in the arm and foot
Sponsors
Leads: Profusa, Inc.
Collaborators: National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI)

This content was sourced from clinicaltrials.gov